Cargando…

Correction to: A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies

Detalles Bibliográficos
Autores principales:	Shimizu, Toshio, Kuboki, Yasutoshi, Lin, Chia-Chi, Yonemori, Kan, Yanai, Tomoko, Faller, Douglas V., Dobler, lwona, Gupta, Neeraj, Sedarati, Farhad, Kim, Kyu-pyo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217764/ https://www.ncbi.nlm.nih.gov/pubmed/35412171 http://dx.doi.org/10.1007/s11523-022-00881-2

Ejemplares similares

A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies
por: Shimizu, Toshio, et al.
Publicado: (2021)

Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer
por: Voss, Martin H., et al.
Publicado: (2020)

Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy
por: Choueiri, Toni K, et al.
Publicado: (2022)

Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours
por: Moore, Kathleen N, et al.
Publicado: (2018)

Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study
por: Kuboki, Yasutoshi, et al.
Publicado: (2022)

Hyperuricemic Renal Failure in Nonhematologic Solid Tumors: A Case Report and Review of the Literature
por: Saini, Neeraj, et al.
Publicado: (2012)

TAK228 enhances antitumor activity of eribulin in triple negative breast cancer
por: Owusu-Brackett, Nicci, et al.
Publicado: (2019)

Systematic review of the clinical effect of glucocorticoids on nonhematologic malignancy
por: Keith, Bruce D
Publicado: (2008)

Metastases to the Breast from Extramammary Nonhematological Malignancies: Case Series
por: Wan, Xue, et al.
Publicado: (2020)

Spectrum of nonhematological pediatric tumors: A clinicopathologic study of 385 cases
por: Punia, Rajpal Singh, et al.
Publicado: (2014)

mTOR inhibition by TAK‐228 is effective against growth, survival and angiogenesis in preclinical retinoblastoma models
por: Tang, Lanlan, et al.
Publicado: (2022)

Metabolic toxicities in patients undergoing treatment for nonhematological malignancy: A cross-sectional study
por: Gupta, Subhash, et al.
Publicado: (2016)

Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies
por: Alhalabi, Omar, et al.
Publicado: (2023)

The bone marrow aspirate and biopsy in the diagnosis of unsuspected nonhematologic malignancy: A clinical study of 19 cases
por: Ozkalemkas, Fahir, et al.
Publicado: (2005)

The Novel Oral mTORC1/2 Inhibitor TAK-228 Reverses Trastuzumab Resistance in HER2-Positive Breast Cancer Models
por: Sanz-Álvarez, Marta, et al.
Publicado: (2021)

The decay scheme of $^{228}$Fr and $K=0$ bands in $^{228}$Ra
por: Ruchowska, E, et al.
Publicado: (1982)

Pharmacokinetics and tolerability of the dual TORC1/2 inhibitor sapanisertib in combination with the MEK inhibitor trametinib in dogs
por: Wei, Bih-Rong, et al.
Publicado: (2022)

Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies
por: de Jonge, Maja J. A., et al.
Publicado: (2019)

Pilot clinical trial and phenotypic analysis in chemotherapy-pretreated, metastatic triple-negative breast cancer patients treated with oral TAK-228 and TAK-117 (PIKTOR) to increase DNA damage repair deficiency followed by cisplatin and nab paclitaxel
por: Lang, Jessica D., et al.
Publicado: (2023)

Phase 1 Study to Evaluate the Effect of the Investigational Anticancer Agent Sapanisertib on the QTc Interval in Patients With Advanced Solid Tumors
por: Patel, Chirag, et al.
Publicado: (2020)

Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies
por: Faessel, Hélène M., et al.
Publicado: (2019)

Enhancing CDK4/6 inhibitor therapy for medulloblastoma using nanoparticle delivery and scRNA-seq–guided combination with sapanisertib
por: Lim, Chaemin, et al.
Publicado: (2022)

Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors
por: Zhou, Xiaofei, et al.
Publicado: (2022)

ATRT-02. THE DUAL MTORC1/2 INHIBITOR, TAK-228 COMBINES SYNERGISTICALLY WITH THE BH3 MIMETIC, OBATOCLAX TO IMPROVE SURVIVAL IN MICE BEARING ORTHOTOPIC XENOGRAFTS OF AT/RT
por: Findlay, Tyler, et al.
Publicado: (2021)

Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine
por: Handa, Hiroshi, et al.
Publicado: (2022)

T228. VARIABILITY AND UNDERUTILISATION OF CLOZAPINE IN SPAIN
por: Sanz-Fuentenebro, Francisco Javier, et al.
Publicado: (2018)

Health Tract, No. 228: Popular Fallacies
Publicado: (1865)

Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor
por: García-Sáenz, José Á., et al.
Publicado: (2022)

The new neutron-rich isotope $^{228}$Rn
por: García-Borge, M J, et al.
Publicado: (1989)

Study of internal conversion electrons in $^{228}$Ra
por: García-Borge, M J, et al.
Publicado: (1986)

An implanted $^{228}$Ra source for response characterization of bolometers
por: Brofferio, Chiara, et al.
Publicado: (2015)

FK228 from Burkholderia thailandensis MSMB43
por: Liu, Xiang-Yang, et al.
Publicado: (2012)

Quadrupole-deformed and octupole collective bands in $^{228}$Ra
por: Gulda, K, et al.
Publicado: (1998)

PSAT228 Hereditary Hypophosphatemic Rickets: Management in Adults
por: Manas, F N U, et al.
Publicado: (2022)

TAK1ng control: TAK1 restrains NLRP3 activation
por: Mangan, Matthew Stephen, et al.
Publicado: (2018)

DICE: Dual mTorc Inhibition in advanCed/recurrent Epithelial ovarian cancer resistant to standard treatment—a study protocol for a randomised trial investigating a novel therapy called TAK228
por: Fiorentino, Francesca, et al.
Publicado: (2022)

Safety, tolerability, pharmacokinetics and preliminary antitumour activity of an antisense oligonucleotide targeting STAT3 (danvatirsen) as monotherapy and in combination with durvalumab in Japanese patients with advanced solid malignancies: a phase 1 study
por: Nishina, Tomohiro, et al.
Publicado: (2022)

Sitting Time and Waist Circumference Are Associated With Glycemia in U.K. South Asians: Data from 1,228 adults screened for the PODOSA trial
por: Gill, Jason M.R., et al.
Publicado: (2011)

228 PCR Analysis of Microorganisms in Chronic Rhinosinusitis with Nasal Polyps
por: Hirotsu, Mikio, et al.
Publicado: (2012)

Laparoscopic adjustable gastric banding: a report of 228 cases
por: Wang, Xin, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_0j7fhi8oolbcv718ppo6evr4cn